These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28289139)

  • 1. Longitudinal Predictors of Synthetic Cannabinoid Use in Adolescents.
    Ninnemann AL; Jeong Choi H; Stuart GL; Temple JR
    Pediatrics; 2017 Apr; 139(4):. PubMed ID: 28289139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.
    Winstock A; Lynskey M; Borschmann R; Waldron J
    J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Cannabinoid Use Among High School Seniors.
    Palamar JJ; Barratt MJ; Coney L; Martins SS
    Pediatrics; 2017 Oct; 140(4):. PubMed ID: 28893851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
    Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
    Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
    Bassir Nia A; Medrano B; Perkel C; Galynker I; Hurd YL
    J Psychopharmacol; 2016 Dec; 30(12):1321-1330. PubMed ID: 27462088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of synthetic cannabinoid consumption by current cannabis users.
    Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
    Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
    Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
    Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
    Kassai S; Pintér JN; Rácz J; Böröndi B; Tóth-Karikó T; Kerekes K; Gyarmathy VA
    Harm Reduct J; 2017 Feb; 14(1):9. PubMed ID: 28187774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.
    Mensen VT; Vreeker A; Nordgren J; Atkinson A; de la Torre R; Farré M; Ramaekers JG; Brunt TM
    Psychopharmacology (Berl); 2019 Sep; 236(9):2677-2685. PubMed ID: 30968175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Cannabinoids: Use and Predictors in a Community Sample of Young Adults.
    Caviness CM; Tzilos G; Anderson BJ; Stein MD
    Subst Abus; 2015; 36(3):368-73. PubMed ID: 25222129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Risk Behaviors With Synthetic Cannabinoids Versus Marijuana.
    Clayton HB; Lowry R; Ashley C; Wolkin A; Grant AM
    Pediatrics; 2017 Apr; 139(4):. PubMed ID: 28289138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
    Tait RJ; Caldicott D; Mountain D; Hill SL; Lenton S
    Clin Toxicol (Phila); 2016; 54(1):1-13. PubMed ID: 26567470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atrial fibrillation following synthetic cannabinoid abuse.
    Efe TH; Felekoglu MA; Çimen T; Doğan M
    Turk Kardiyol Dern Ars; 2017 Jun; 45(4):362-364. PubMed ID: 28595208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, period, and cohort effects in synthetic cannabinoid use among US adolescents, 2011-2015.
    Keyes KM; Rutherford C; Hamilton A; Palamar JJ
    Drug Alcohol Depend; 2016 Sep; 166():159-67. PubMed ID: 27491817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics of Synthetic Cannabinoid Use in a Large Urban Psychiatric Emergency Setting.
    Manseau MW; Rajparia A; Joseph A; Azarchi S; Goff D; Satodiya R; Lewis CF
    Subst Use Misuse; 2017 May; 52(6):822-825. PubMed ID: 28156305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic cannabinoid withdrawal: a new demand on detoxification services.
    Macfarlane V; Christie G
    Drug Alcohol Rev; 2015 Mar; 34(2):147-53. PubMed ID: 25588420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic cannabinoid and marijuana exposures reported to poison centers.
    Forrester MB; Kleinschmidt K; Schwarz E; Young A
    Hum Exp Toxicol; 2012 Oct; 31(10):1006-11. PubMed ID: 22859662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure.
    Gudsoorkar VS; Perez JA
    Methodist Debakey Cardiovasc J; 2015; 11(3):189-91. PubMed ID: 26634029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marijuana and adolescents.
    Nistler C; Hodgson H; Nobrega FT; Hodgson CJ; Wheatley R; Solberg G
    Minn Med; 2006 Sep; 89(9):49-51. PubMed ID: 17024926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Cannabinoids.
    Mills B; Yepes A; Nugent K
    Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.